Volume 130, Issue 1, Pages (July 2013)

Slides:

Advertisements

Similar presentations

The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes Tae-Min Kim, Peter W. Laird, Peter J. Park Cell Volume 155, Issue.

Advertisements

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Nicoletta Colombo, Martin Gore

Volume 144, Issue 1, Pages (January 2017)

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 148, Issue 1, Pages (January 2018)

Volume 150, Issue 1, Pages (July 2018)

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients.

Volume 151, Issue 1, Pages (October 2018)

Volume 145, Issue 2, Pages (May 2017)

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Volume 138, Issue 1, Pages (July 2015)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Stem Cell Therapies in Clinical Trials: Progress and Challenges

Volume 147, Issue 1, Pages 3-10 (October 2017)

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Volume 148, Issue 1, Pages (January 2018)

Volume 141, Issue 2, Pages (May 2016)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Volume 152, Issue 1, Pages (January 2019)

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

George Blumenschein, MD, John V. Heymach, MD, PhD

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

The origins of multidisciplinary cancer care

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Volume 373, Issue 9658, Pages (January 2009)

Volume 152, Issue 1, Pages (January 2019)

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Volume 142, Issue 2, Pages (August 2016)

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Volume 152, Issue 1, Pages (January 2019)

A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43– 9006) in Previously Treated Non–Small-Cell Lung Cancer Patients: Eastern.

Volume 152, Issue 1, Pages (January 2019)

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Erratum to “Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma” [Gynecol Oncol. 120 (2011) 11–17] Heini Lassus,

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 124, Issue 1, Pages (January 2012)

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Volume 115, Issue 1, Pages (October 2009)

Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial Barbara J.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 130, Issue 1, Pages 252-253 (July 2013) Corrigendum to “A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study” [Gynecol Oncol 127 (2012) 538–543] Robert L. Coleman, Michael W. Sill, Heather A. Lankes, Amanda Nickles Fader, Neil J. Finkler, James S. Hoffman, Peter G. Rose, Gregory P. Sutton, Charles W. Drescher, D. Scott McMeekin, Wei Hu, Michael Deavers, Andrew K. Godwin, R. Katherine Alpaugh, Anil K. Sood Gynecologic Oncology Volume 130, Issue 1, Pages 252-253 (July 2013) DOI: 10.1016/j.ygyno.2013.04.007 Copyright © 2013 Elsevier Inc. Terms and Conditions

Fig. 1 Kaplan–Meier plots depicting the progression-free and overall survival for the 44 evaluable patients on this trial. Gynecologic Oncology 2013 130, 252-253DOI: (10.1016/j.ygyno.2013.04.007) Copyright © 2013 Elsevier Inc. Terms and Conditions